PHARMA MONITOR

Strategic Insights On Pharma Market Trends

By Richa Chaudhary
Month May-24
Content
• Therapy Monitor

• Corporate Monitor

• Brand Monitor
Therapy Monitor
Evolution Index (EI)
In the pharmaceutical industry, the Evolution Index is a crucial tool for strategic decision-making.
It measures a product's growth relative to its market, offering valuable insights for maximizing
profitability and navigating market competition effectively. With a range from-100 to positive
values, this index enables companies to make informed, flexible decisions and stay ahead in a
competitive landscape.

Analyzing the evolution index over time in combination with the current sales gives us clear
picture how the company products are competing on the market against the total market sales.

100 + (Brand Growth%) x 100)

Evolution Index =
100 + (Market Growth%) x 100)
Therapy Monitor MTH May 24
SUPER GROUP VAL % Gr % Contri EI Incr Gain
o Weather events like large storms, heat 16711.9 5.2% 830.7
waves, rains & droughts lead to sudden CARDIAC 2275.7 6.2% 13.62% 101% 132.5
change in weather across the country. Anti GASTRO INTESTINAL 2029.3 4.7% 12.14% 100% 91.8
– Infective followed by Respiratory ANTI-INFECTIVES 2013.3 12.0% 12.05% 106% 215.6
ANTI DIABETIC 1570.5 4.8% 9.40% 100% 72.5
registered highest growths for the month. VITAMINS / MINERALS / NUTRIENTS 1451.8 0.3% 8.69% 95% 3.8
RESPIRATORY 1222.6 10.2% 7.32% 105% 113.5
o Excessive summer heat in May 24 lead to PAIN / ANALGESICS 1157.7 2.7% 6.93% 98% 30.2
Common pulmonology issues like DERMA 1101.4 4.2% 6.59% 99% 44.3
NEURO / CNS 1034.4 2.4% 6.19% 97% 24.5
bronchitis, asthma, chronic obstructive GYNAECOLOGICAL 541.2 -2.7% 3.24% 92% -15.3
pulmonary diseases, and emphysema BLOOD RELATED 517.5 5.9% 3.10% 101% 28.9
leading to 10% growth for Respiratory TA ANTI-NEOPLASTICS 414.0 17.3% 2.48% 111% 61.1
OPHTHAL / OTOLOGICALS 301.4 2.5% 1.80% 97% 7.2
HORMONES 279.7 5.8% 1.67% 101% 15.3
o Anti- Infective drugs saw increased usage UROLOGY 274.6 6.6% 1.64% 101% 17.0
as more cases of Fungal Infections, URTI, VACCINES 134.5 -7.9% 0.80% 88% -11.5
Fever were reported. Antimycobacterial OTHERS 134.1 7.5% 0.80% 102% 9.3
drugs usage also went up with increased SEX STIMULANTS / REJUVENATORS 109.0 -7.4% 0.65% 88% -8.8
STOMATOLOGICALS 108.1 -3.2% 0.65% 92% -3.6
cases of TB reported in May 24 ANTI MALARIALS 40.9 5.6% 0.24% 100% 2.2

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
Corporate Monitor
MTH May 24

#1 - 20 Rank Corporate VAL % Gr % MS G/L %MS EI Incr Gain

16711.9 5.2% 100% 100% 830.7

1 SUN* 1425.0 5.1% 8.5% 100% 68.8
o IPM exhibited a growth of 5.2%, however 2 ABBOTT* 1034.5 -0.1% 6.2% 95% -0.7
corporates like Torrent, Alkem, Macleods & 3 MANKIND 883.5 4.9% 5.3% 100% 41.4
USV posted a robust double-digit growth 4 CIPLA 840.2 9.3% 5.0% 104% 71.5
for MTH May 24 5 TORRENT 683.8 11.6% 4.1% 106% 71.0
6 ZYDUS* 654.4 3.8% 3.9% 99% 23.7
7 INTAS 601.4 6.5% 3.6% 101% 36.5
8 ALKEM* 599.0 11.7% 3.6% 106% 62.8
o Highest incr gain over LYSM was registered 9 LUPIN 598.0 6.1% 3.6% 101% 34.3
by Cipla - 71.5 Cr, Torrent - 71 Cr, Alkem - 10 MACLEODS 557.3 12.7% 3.3% 107% 62.7
62.8 Cr, Macleods - 62.7 Cr & USV - 57 Cr 11 ARISTO 487.7 7.7% 2.9% 102% 34.9
12 DR. REDDYS 481.1 2.1% 2.9% 97% 9.9
13 EMCURE* 480.4 9.7% 2.9% 104% 42.4
14 USV 392.7 17.0% 2.3% 111% 57.0
o Eris LS entered the Top 20 club 15 GSK 384.5 2.7% 2.3% 98% 10.0
16 GLENMARK 338.6 8.9% 2.0% 103% 27.7
17 IPCA 303.2 7.0% 1.8% 102% 19.7
18 MICRO 280.6 9.8% 1.7% 104% 25.1
19 PFIZER* 262.1 -5.1% 1.6% 90% -14.2
20 ERIS LS 247.2 1.7% 1.5% 97% 4.1
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH May 24

#21 - 40 Rank Corporate VAL % Gr % MS G/L %MS EI Incr Gain

16711.9 5.2% 100% 100% 830.7

21 SANOFI INDIA 227.0 6.4% 1.4% 101% 13.6
o Fourrts continued with highest growth 22 ALEMBIC 187.7 13.0% 1.1% 107% 21.5
among 21 to 40 rank corporates in the IPM 23 FDC 156.6 13.1% 0.9% 107% 18.1
for the month of May as well. Other 24 LA RENON 128.0 1.2% 0.8% 96% 1.5
corporates like Hetero, Alembic, FDC, 25 HIMALAYA 124.2 7.0% 0.7% 102% 8.2
Corona, Bharat Serums and Natco 26 CADILA 120.4 5.0% 0.7% 100% 5.8
27 AJANTA 118.1 -1.3% 0.7% 94% -1.6
registered a double digit growth.
28 JB CHEMICALS 112.8 0.5% 0.7% 96% 0.6
o Ajanta and Medley registered a degrowth 29 HETERO 111.5 25.1% 0.7% 119% 22.4
compared to LYSM 30 INDOCO 104.5 6.5% 0.6% 101% 6.4
31 CORONA 103.1 11.6% 0.6% 106% 10.7
o Most corporates held on to MS for May 24. 32 FOURRTS 97.7 33.9% 0.6% 127% 24.8
Alembic, FDC, Hetero and Fourrts gained 33 BHARAT SERUMS 96.4 11.6% 0.6% 106% 10.1
34 FRANCO 93.9 1.6% 0.6% 97% 1.5
%MS and Incr val
35 HEGDE & HEGDE 86.0 3.1% 0.5% 98% 2.6
36 BLUE CROSS 85.1 5.1% 0.5% 100% 4.1
37 MEDLEY 84.1 -5.8% 0.5% 90% -5.2
38 NATCO 81.5 11.1% 0.5% 106% 8.2
39 SYSTOPIC 78.8 5.7% 0.5% 100% 4.3
40 WALLACE* 73.8 0.8% 0.4% 96% 0.6
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH May 24

#41 - 60 Rank Corporate VAL % Gr % MS G/L %MS EI Incr Gain

16711.9 5.2% 100% 100% 830.7

41 APEX 72.2 -4.9% 0.4% 90% -3.7
42 WIN-MEDICARE 69.7 2.5% 0.4% 97% 1.7
o Mylan, Fresenius, Bayer Zydus, Troikaa and 43 MEYER 66.9 -1.7% 0.4% 93% -1.2
Allergan exhibited growth over LYSM. 44 FRESENIUS 65.7 20.6% 0.4% 115% 11.2
45 ASTRAZENECA 64.8 -8.2% 0.4% 87% -5.8
o Mylan’s Anti-Hypotensive brand Inramed 46 BOEHRINGER INGELHEIM 60.9 2.5% 0.4% 97% 1.5
posted exceptional performance leading to 47 DANONE 60.5 -2.9% 0.4% 92% -1.8
59% growth for the corporate, while 48 BAYER ZYDUS 60.0 13.0% 0.4% 107% 6.9
Fresenius performed well with its Analgesic 49 NOVARTIS* 59.5 -6.3% 0.4% 89% -4.0
portfolio 50 PROCTER AND GAMBLE HEALTH
57.8 -3.5% 0.3% 92% -2.1
51 TROIKAA 54.5 14.0% 0.3% 108% 6.7
o Apex, Meyer, Novartis, BI, Danone, Piramal, 52 ALLERGAN 54.3 10.4% 0.3% 105% 5.1
Janssen, Raptakos and Akumentis saw a 53 MSD* 53.7 1.8% 0.3% 97% 1.0
degrowth over MTH Apr 23 54 PIRAMAL 51.9 -11.8% 0.3% 84% -6.9
55 PHARMED 51.8 0.1% 0.3% 95% 0.1
56 JANSSEN 50.8 -11.0% 0.3% 85% -6.2
57 MERCK 48.4 5.4% 0.3% 100% 2.5
58 RAPTAKOS 44.6 -9.5% 0.3% 86% -4.7
59 MYLAN 44.6 59.3% 0.3% 151% 16.6
60 WOCKHARDT 43.1 9.3% 0.3% 104% 3.7
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH May 24

#61 - 80 Rank Corporate VAL % Gr % MS G/L %MS EI Incr Gain

16711.9 5.2% 100% 100% 830.7

61 AKUMENTIS 42.5 -1.4% 0.3% 94% -0.6
62 SAMARTH 38.2 19.5% 0.2% 114% 6.2
o Among the 60th to 80th rank corporates 63 RPG 38.0 0.3% 0.2% 95% 0.1
Samarth LS, Centaur, Aurobindo Pharma, 64 CENTAUR 37.0 20.3% 0.2% 114% 6.2
Serum Institute, Albert David, Neon LS & 65 SERUM INSTITUTE 36.0 11.1% 0.2% 106% 3.6
Modi Mundi registered a double-digit 66 ALBERT DAVID 35.6 11.5% 0.2% 106% 3.7
growth over LYSM 67 INTEGRACE HEALTH 34.6 3.7% 0.2% 99% 1.2
68 EAST INDIA 34.0 2.7% 0.2% 98% 0.9
o Aurobindo’s analgesic portfolio performed 69 KLM 32.9 8.1% 0.2% 103% 2.5
well, while Centaur’s growth was led by its 70 MANEESH* 32.9 -8.6% 0.2% 87% -3.1
cough and cold basket brand Sinarest 71 TABLETS INDIA 32.2 -1.3% 0.2% 94% -0.4
72 Aurobindo Pharmaceuticals Ltd.
32.1 24.2% 0.2% 118% 6.2
o Akumentis, Tablets India, Biological E, 73 UNIMED TL 30.6 5.6% 0.2% 100% 1.6
Leeford HC, saw a degrowth over LYSM 74 SERDIA 30.4 3.4% 0.2% 98% 1.0
75 WALTER BUSHNELL 29.5 5.2% 0.2% 100% 1.5
76 NEON 29.1 14.6% 0.2% 109% 3.7
77 BIOLOGICAL E 28.7 -11.6% 0.2% 84% -3.8
78 LEEFORD HC 26.6 -15.9% 0.2% 80% -5.0
79 MODI MUNDI 26.3 15.9% 0.2% 110% 3.6
80 LINUX LAB. 25.5 3.1% 0.2% 98% 0.8
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH May 24

#81 - 100 Rank Corporate VAL % Gr % MS G/L %MS EI Incr Gain

16711.9 5.2% 100% 100% 830.7

81 MSN 23.7 -9.2% 0.1% 86% -2.4
82 GENO 23.2 0.3% 0.1% 95% 0.1
o Gufic Biosciences along with Galderma, 83 MED MANOR 22.1 6.7% 0.1% 101% 1.4
Unison, Celon Labs, UNSC & Overseas 84 UNS 21.7 16.9% 0.1% 111% 3.1
even in the month of May 24 85 UNISON 21.3 14.2% 0.1% 109% 2.7
86 GUFIC BIOSCIENCE 21.2 16.1% 0.1% 110% 2.9
o Celon’s growth was led by its anti- 87 OZONE 20.9 1.9% 0.1% 97% 0.4
neoplastics portfolio while Gufic’s growth 88 AIMIL 20.2 -9.7% 0.1% 86% -2.2
was led by its Anti-Bacterial portfolio 89 CHARAK 19.3 -9.1% 0.1% 86% -1.9
90 KEPLER HC 19.2 -3.0% 0.1% 92% -0.6
o Alniche LS, Lincoln, ICPA, Fusion HC along 91 SHREYA 19.1 -3.2% 0.1% 92% -0.6
struggled to match performance of LYSM 92 GALDERMA 19.0 2.0% 0.1% 97% 0.4
93 LLOYD HC 18.8 0.2% 0.1% 95% 0.0
94 CELON LABS 17.7 34.1% 0.1% 127% 4.5
95 OVERSEAS 16.3 10.3% 0.1% 105% 1.5
96 JAGSONPAL 15.8 -12.9% 0.1% 83% -2.3
97 ICPA 15.6 -16.2% 0.1% 80% -3.0
98 FUSION HEALTHCARE 15.5 -11.9% 0.1% 84% -2.1
99 ALNICHE LIFE SCIENCE 15.3 -28.2% 0.1% 68% -6.0
100 LINCOLN 15.2 -16.8% 0.1% 79% -3.1
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor
Brand Monitor #1 – 20
MTH MAY 24
EI
% MS in G/L % MS
RANK CORPORATE COMPANY BRAND SUPER GROUP (SG) SG GR% VAL % GR against Incr Gain
IPM in IPM
SG
16711.9 5.2% 100% 830.7
1 USV USV PVT LTD GLYCOMET GP ANTI DIABETIC 4.8% 70.1 7.1% 0.4% 102% 4.7
2 GSK GLAXOSMITHKLINE PHARMACEUTICALS AUGMENTIN ANTI-INFECTIVES 12.0% 64.5 29.3% 0.4% 115% 14.6
3 HIMALAYA HIMALAYA DRUG COMPANY LIV.52 GASTRO INTESTINAL 4.7% 55.0 16.4% 0.3% 111% 7.8
4 SUN* RANBAXY LABORATORIES LTD ROSUVAS CARDIAC 6.2% 54.2 28.1% 0.3% 121% 11.9
5 CIPLA CIPLA LTD. FORACORT RESPIRATORY 10.2% 49.2 4.1% 0.3% 94% 1.9
6 MANKIND MANKIND PHARMACEUTICALS LTD. MANFORCE SEX STIMULANTS / REJUVENATORS -7.4% 48.5 -18.8% 0.3% 88% -11.2
7 ABBOTT* ABBOTT INDIA LTD. UDILIV GASTRO INTESTINAL 4.7% 47.3 16.1% 0.3% 111% 6.5
8 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONOCEF ANTI-INFECTIVES 12.0% 44.2 23.1% 0.3% 110% 8.3
9 ABBOTT* ABBOTT INDIA LTD. THYRONORM HORMONES 5.8% 43.8 7.5% 0.3% 102% 3.1
10 ALKEM* ALKEM LABORATORIES LTD. PAN GASTRO INTESTINAL 4.7% 43.6 18.4% 0.3% 113% 6.8
11 ABBOTT* NOVO NORDISK INDIA PVT LTD MIXTARD ANTI DIABETIC 4.8% 43.6 -10.5% 0.3% 85% -5.1
12 EMCURE* EMCURE PHARMACEUTICALS LTD OROFER-XT BLOOD RELATED 5.9% 42.1 45.1% 0.3% 137% 13.1
13 FDC FDC LTD. ELECTRAL GASTRO INTESTINAL 4.7% 41.4 24.7% 0.2% 119% 8.2
14 WIN-MEDICARE WIN-MEDICARE PVT. LTD. BETADINE DERMA 4.2% 39.5 -2.0% 0.2% 94% -0.8
15 USV USV PVT LTD ECOSPRIN AV CARDIAC 6.2% 38.1 24.1% 0.2% 117% 7.4
16 ALKEM* ALKEM LABORATORIES LTD. PAN D GASTRO INTESTINAL 4.7% 37.0 25.7% 0.2% 120% 7.6
17 IPCA IPCA LABORATORIES PVT LTD. ZERODOL SP PAIN / ANALGESICS 2.7% 36.5 11.2% 0.2% 108% 3.7
18 ABBOTT* NOVO NORDISK INDIA PVT LTD RYZODEG ANTI DIABETIC 4.8% 36.3 0.4% 0.2% 96% 0.1
19 ABBOTT* NOVO NORDISK INDIA PVT LTD RYBELSUS ANTI DIABETIC 4.8% 35.2 42.4% 0.2% 136% 10.5
20 SANOFI INDIA SANOFI INDIA LTD. LANTUS ANTI DIABETIC 4.8% 34.5 1.8% 0.2% 97% 0.6

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor #21 – 40
MTH MAY 24
EI
% MS in G/L % MS
RANK CORPORATE COMPANY BRAND SUPER GROUP (SG) SG GR% VAL % GR against Incr Gain
IPM in IPM
SG
16711.9 5.2% 100% 830.7
21 ARISTO ARISTO PHARMACEUTICALS PVT.LTD PANTOP GASTRO INTESTINAL 4.7% 34.2 11.5% 0.2% 106% 3.5
22 ALKEM* ALKEM LABORATORIES LTD. CLAVAM ANTI-INFECTIVES 12.0% 33.8 13.5% 0.2% 101% 4.0
23 CADILA CADILA PHARMACEUTICALS LTD ACILOC GASTRO INTESTINAL 4.7% 33.5 14.3% 0.2% 109% 4.2
24 CIPLA CIPLA LTD. BUDECORT RESPIRATORY 10.2% 32.8 21.3% 0.2% 110% 5.8
25 JANSSEN JANSSEN ULTRACET PAIN / ANALGESICS 2.7% 32.0 -5.0% 0.2% 92% -1.7
26 GSK GLAXOSMITHKLINE PHARMACEUTICALS CALPOL PAIN / ANALGESICS 2.7% 31.2 -1.7% 0.2% 96% -0.6
27 CIPLA CIPLA LTD. DUOLIN RESPIRATORY 10.2% 31.2 12.7% 0.2% 102% 3.5
28 SUN* SUN PHARMA LABORATORIES LTD. LEVIPIL NEURO / CNS 2.4% 30.7 6.2% 0.2% 104% 1.8
29 MSD* MSD PHARMACEUTICALS PRIVATE LTD. JANUMET ANTI DIABETIC 4.8% 30.7 4.9% 0.2% 100% 1.4
30 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA CARDIAC 6.2% 30.3 7.4% 0.2% 101% 2.1
31 ABBOTT* NOVO NORDISK INDIA PVT LTD TRESIBA ANTI DIABETIC 4.8% 29.3 45.6% 0.2% 139% 9.2
32 APEX APEX LABORATORIES LTD. ZINCOVIT VITAMINS / MINERALS / NUTRIENTS 0.3% 28.8 -9.6% 0.2% 90% -3.1
33 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MIKACIN ANTI-INFECTIVES 12.0% 28.2 5.0% 0.2% 94% 1.3
34 PFIZER* PFIZER LTD BECOSULES VITAMINS / MINERALS / NUTRIENTS 0.3% 28.0 -2.0% 0.2% 98% -0.6
35 FRANCO FRANCO INDIAN PHARMACEUTICALS DEXORANGE BLOOD RELATED 5.9% 27.8 -5.3% 0.2% 89% -1.6
36 SUN* RANBAXY LABORATORIES LTD VOLINI PAIN / ANALGESICS 2.7% 27.7 -19.1% 0.2% 79% -6.5
37 ASTRAZENECA ASTRAZENECA PHARMA INDIA LTD BRILINTA CARDIAC 6.2% 27.6 12.4% 0.2% 106% 3.0
38 TORRENT TORRENT PHARMACEUTICALS LTD. CHYMORAL FORTE PAIN / ANALGESICS 2.7% 27.2 21.2% 0.2% 118% 4.8
39 DANONE DANONE DEXOLAC 1 VITAMINS / MINERALS / NUTRIENTS 0.3% 27.1 13.4% 0.2% 113% 3.2
40 TORRENT TORRENT PHARMACEUTICALS LTD. SHELCAL VITAMINS / MINERALS / NUTRIENTS 0.3% 26.9 -1.9% 0.2% 98% -0.5

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor #41 – 60
MTH MAY 24
EI
% MS in G/L % MS
RANK CORPORATE COMPANY BRAND SUPER GROUP (SG) SG GR% VAL % GR against Incr Gain
IPM in IPM
SG
16711.9 5.2% 100% 830.7
41 LUPIN LUPIN LTD GLUCONORM-G ANTI DIABETIC 4.8% 26.7 0.8% 0.2% 96% 0.2
42 GSK GLAXOSMITHKLINE PHARMACEUTICALS BETNOVATE N DERMA 4.2% 26.6 12.7% 0.2% 108% 3.0
43 MANKIND MANKIND PHARMACEUTICALS LTD. PREGA NEWS OTHERS 7.5% 26.4 -10.9% 0.2% 83% -3.2
44 ABBOTT* NOVO NORDISK INDIA PVT LTD NOVOMIX ANTI DIABETIC 4.8% 25.6 -6.2% 0.2% 89% -1.7
45 MICRO MICRO LABS LTD DOLO PAIN / ANALGESICS 2.7% 24.9 11.9% 0.1% 109% 2.7
46 ABBOTT* ABBOTT INDIA LTD. VERTIN NEURO / CNS 2.4% 24.6 -0.9% 0.1% 97% -0.2
47 GSK GLAXOSMITHKLINE PHARMACEUTICALS T BACT DERMA 4.2% 24.5 -20.5% 0.1% 76% -6.3
48 MANKIND MANKIND PHARMACEUTICALS LTD. MOXIKIND CV ANTI-INFECTIVES 12.0% 23.9 10.2% 0.1% 98% 2.2
49 USV USV PVT LTD ECOSPRIN GOLD CARDIAC 6.2% 23.8 35.6% 0.1% 128% 6.2
50 ABBOTT* ABBOTT INDIA LTD. DUPHALAC GASTRO INTESTINAL 4.7% 23.6 7.0% 0.1% 102% 1.5
51 SUN* SUN PHARMA LABORATORIES LTD. GEMER ANTI DIABETIC 4.8% 23.5 -6.6% 0.1% 89% -1.7
52 PFIZER* PFIZER LTD MINIPRESS XL CARDIAC 6.2% 22.3 0.7% 0.1% 95% 0.2
53 SUN* SUN PHARMA LABORATORIES LTD. SUSTEN GYNAECOLOGICAL -2.7% 22.3 -1.8% 0.1% 101% -0.4
54 MANKIND MANKIND PHARMACEUTICALS LTD. UNWANTED KIT GYNAECOLOGICAL -2.7% 21.9 2.4% 0.1% 105% 0.5
55 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA H CARDIAC 6.2% 21.9 21.8% 0.1% 115% 3.9
56 INTAS INTAS PHARMACEUTICALS LTD LEVERA NEURO / CNS 2.4% 21.8 1.5% 0.1% 99% 0.3
57 INTAS INTAS PHARMACEUTICALS LTD GABAPIN NT NEURO / CNS 2.4% 21.8 18.4% 0.1% 116% 3.4
58 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA AM CARDIAC 6.2% 21.6 8.0% 0.1% 102% 1.6
59 FDC FDC LTD. ZIFI ANTI-INFECTIVES 12.0% 21.5 2.9% 0.1% 92% 0.6
60 ALKEM* ALKEM LABORATORIES LTD. A TO Z NS VITAMINS / MINERALS / NUTRIENTS 0.3% 21.4 8.1% 0.1% 108% 1.6

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor #61 – 80
MTH MAY 24
EI
% MS in G/L % MS
RANK CORPORATE COMPANY BRAND SUPER GROUP (SG) SG GR% VAL % GR against Incr Gain
IPM in IPM
SG
16711.9 5.2% 100% 830.7
61 GSK GLAXOSMITHKLINE PHARMACEUTICALS BETNOVATE C DERMA 4.2% 21.3 -4.0% 0.1% 92% -0.9
62 CIPLA CIPLA LTD. ASTHALIN RESPIRATORY 10.2% 21.1 5.7% 0.1% 96% 1.1
63 USV USV PVT LTD GLYCOMET TRIO ANTI DIABETIC 4.8% 21.0 12.2% 0.1% 107% 2.3
64 INTAS INTAS PHARMACEUTICALS LTD ZORYL-M ANTI DIABETIC 4.8% 21.0 -2.8% 0.1% 93% -0.6
65 SUN* RANBAXY LABORATORIES LTD MOXCLAV ANTI-INFECTIVES 12.0% 20.9 31.3% 0.1% 117% 5.0
66 JB CHEMICALS JB CHEMICALS CILACAR CARDIAC 6.2% 20.8 0.4% 0.1% 95% 0.1
67 ABBOTT* ABBOTT INDIA LTD. DUPHASTON GYNAECOLOGICAL -2.7% 20.7 -0.7% 0.1% 102% -0.1
68 SUN* SUN PHARMA LABORATORIES LTD. PANTOCID GASTRO INTESTINAL 4.7% 20.3 6.1% 0.1% 101% 1.2
69 SANOFI INDIA SANOFI INDIA LTD. ALLEGRA RESPIRATORY 10.2% 20.3 17.2% 0.1% 106% 3.0
70 ALKEM* ALKEM LABORATORIES LTD. XONE ANTI-INFECTIVES 12.0% 20.0 30.6% 0.1% 117% 4.7
71 BOEHRINGER INGELHEIM BOEHRINGER INGELHEIM JARDIANCE ANTI DIABETIC 4.8% 19.5 5.3% 0.1% 100% 1.0
72 ABBOTT* ABBOTT INDIA LTD. CREMAFFIN PLUS GASTRO INTESTINAL 4.7% 19.5 10.9% 0.1% 106% 1.9
73 ZYDUS* ZYDUS CADILA - ZHL LIPAGLYN CARDIAC 6.2% 19.4 -13.9% 0.1% 81% -3.1
74 ABBOTT* ABBOTT HEALTHCARE PVT. LTD STEMETIL GASTRO INTESTINAL 4.7% 19.4 5.5% 0.1% 101% 1.0
75 SUN* SUN PHARMA LABORATORIES LTD. MONTEK-LC RESPIRATORY 10.2% 19.4 23.7% 0.1% 112% 3.7
76 GSK GLAXOSMITHKLINE PHARMACEUTICALS ELTROXIN HORMONES 5.8% 19.4 -4.9% 0.1% 90% -1.0
77 CIPLA CIPLA LTD. DYTOR CARDIAC 6.2% 19.1 2.2% 0.1% 96% 0.4
78 IPCA IPCA LABORATORIES PVT LTD. ZERODOL P PAIN / ANALGESICS 2.7% 18.9 1.8% 0.1% 99% 0.3
79 ALKEM* ALKEM LABORATORIES LTD. TAXIM O ANTI-INFECTIVES 12.0% 18.9 -1.4% 0.1% 88% -0.3
80 MANKIND MANKIND PHARMACEUTICALS LTD. AMLOKIND-AT CARDIAC 6.2% 18.9 14.6% 0.1% 108% 2.4

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor #81 – 100
MTH MAY 24
EI
% MS in G/L % MS
RANK CORPORATE COMPANY BRAND SUPER GROUP (SG) SG GR% VAL % GR against Incr Gain
IPM in IPM
SG
16711.9 5.2% 100% 830.7
81 TORRENT TORRENT PHARMACEUTICALS LTD. SHELCAL XT VITAMINS / MINERALS / NUTRIENTS 0.3% 18.8 3.7% 0.1% 103% 0.7
82 MACLEODS MACLEODS PHARMACEUTICALS PVT.LTD MEROMAC ANTI-INFECTIVES 12.0% 18.8 34.7% 0.1% 120% 4.8
83 PFIZER* PFIZER LTD COREX DX RESPIRATORY 10.2% 18.8 23.2% 0.1% 112% 3.5
84 TORRENT TORRENT PHARMACEUTICALS LTD. NEXPRO RD GASTRO INTESTINAL 4.7% 18.8 16.1% 0.1% 111% 2.6
85 MANKIND MANKIND PHARMACEUTICALS LTD. DYDROBOON GYNAECOLOGICAL -2.7% 18.6 -3.6% 0.1% 99% -0.7
86 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MERO ANTI-INFECTIVES 12.0% 18.5 31.5% 0.1% 117% 4.4
87 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONOCEF SB ANTI-INFECTIVES 12.0% 18.5 6.8% 0.1% 95% 1.2
88 TORRENT TORRENT PHARMACEUTICALS LTD. NIKORAN CARDIAC 6.2% 18.3 12.6% 0.1% 106% 2.1
89 EMCURE* ZUVENTUS HEALTHCARE LTD BEVON VITAMINS / MINERALS / NUTRIENTS 0.3% 18.3 2.9% 0.1% 103% 0.5
90 ALEMBIC ALEMBIC LTD AZITHRAL ANTI-INFECTIVES 12.0% 18.3 11.8% 0.1% 100% 1.9
91 BLUE CROSS BLUE CROSS LABORATORIES LTD MEFTAL SPAS GASTRO INTESTINAL 4.7% 18.3 -1.9% 0.1% 94% -0.4
92 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONTAZ ANTI-INFECTIVES 12.0% 18.2 3.4% 0.1% 92% 0.6
93 SANOFI INDIA SANOFI INDIA LTD. COMBIFLAM PAIN / ANALGESICS 2.7% 17.8 3.2% 0.1% 100% 0.5
94 DR. REDDYS DR. REDDYS LABORATORIES LTD ECONORM GASTRO INTESTINAL 4.7% 17.7 2.8% 0.1% 98% 0.5
95 CIPLA CIPLA LTD. MONTAIR LC RESPIRATORY 10.2% 17.6 3.7% 0.1% 94% 0.6
96 GSK GLAXOSMITHKLINE PHARMACEUTICALS CEFTUM ANTI-INFECTIVES 12.0% 17.4 47.0% 0.1% 131% 5.5
97 SUN* SUN PHARMA LABORATORIES LTD. SOMPRAZ D GASTRO INTESTINAL 4.7% 17.3 8.2% 0.1% 103% 1.3
98 SUN* RANBAXY LABORATORIES LTD SILODAL D UROLOGY 6.6% 17.1 1.3% 0.1% 95% 0.2
99 CIPLA CIPLA LTD. SEROFLO RESPIRATORY 10.2% 17.0 2.4% 0.1% 93% 0.4
100 EMCURE* ZUVENTUS HEALTHCARE LTD ZOSTUM ANTI-INFECTIVES 12.0% 16.9 33.2% 0.1% 119% 4.2

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Stars of the month

Incremental Gain % MS Gain Highest EI

• Augmentin
• Rosuvas
• Augmentin • Rosuvas
• Orofer XT
• Rosuvas • Monocef
• Rybelsus
• Orofer XT • Orofer XT
• Tresiba
• Rybelsus • Electral
• Ecosprin Gold
• Tresiba • Pan D
• Ceftum
• Rybelsus
• Tresiba
 Thank you

Richa Chaudhary
richac@pharmarack.com
+91-9769797951
Visit us at: www.pharmarack.com

Visit us at: www.pharmarack.com